IC
PRME icon

Ikarian Capital’s Prime Medicine PRME Stock Holding History

Ikarian Capital’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-150,000
Closed -$831K – 211
2025
Q3 		$831K Buy
+150,000
New +$609K 0.08% 124

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Ikarian Capital's PRME Position: Q4 2025 in Review

Ikarian Capital sold out of Prime Medicine (PRME) in Q4 2025, closing a stake of 150,000 shares — an estimated $831K sold.

Ikarian Capital first reported a position in PRME in Q3 2025 and held it in 1 quarter. The position peaked at $831K in Q3 2025. 183 funds tracked by Wall St. Rank hold PRME as of Q4 2025.

  • Ikarian Capital reported no remaining Prime Medicine position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 150,000 Prime Medicine shares in Q4 2025, an estimated $831K.
  • Ikarian Capital first reported a position in Prime Medicine in Q3 2025 and held it in 1 quarter.
  • Ikarian Capital's Prime Medicine position peaked at $831K in Q3 2025.
  • 183 funds tracked by Wall St. Rank held Prime Medicine as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.